Philip Morris International (PMI) has acquired inhaled drug developer OtiTopic, as "part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory drug delivery Beyond Nicotine," the company said. PMI recently announced a £1 billion offer for inhalation CDMO … [Read more...] about Philip Morris acquires Asprihale developer OtiTopic
Business
Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye
Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma's OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes a $17.5 million upfront payment and up to $204.8 million in milestone payments and royalties. Earlier this year, Ji Xing acquired … [Read more...] about Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye
Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry of Health, Labour and Welfare approved Arikayce for that indication in March 2021. The company also … [Read more...] about Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials
NRx, MannKind partner on possible Zyesami aviptadil DPI
MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind's Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its facility in Danbury, CT, USA. TFF Pharmaceuticals had previously announced that it was conducting a feasibility study to … [Read more...] about NRx, MannKind partner on possible Zyesami aviptadil DPI
Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German company AdVita Lifescience, which has been developing inhaled aviptadil for human and veterinary use, with Relief citing the … [Read more...] about Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
Sanofi to acquire Translate Bio
Sanofi has agreed to pay approximately $3.2 billion for Translate Bio, which is developing inhaled mRNA therapies for cystic fibrosis, primary ciliary dyskinesia, and pulmonary arterial hypertension in addition to a number of intramuscular mRNA vaccines, including vaccines against COVID-19 and influenza. Sanofi is currently partnered with Translate on the … [Read more...] about Sanofi to acquire Translate Bio
Glenmark acquires rights to market SaNOtize’s nitric oxide nasal spray for COVID-19 in a number of Asian markets
Glenmark Pharmaceuticals has acquired the rights to manufacture and sell SaNOtize's nitric oxide nasal spray (NONS) in India and at least a dozen other markets in Asia for the treatment of COVID-19, the companies have announced. Glenmark expects to be ready to launch the nasal spray as "FabiSpray" in India by the fourth quarter of this year following completion of a … [Read more...] about Glenmark acquires rights to market SaNOtize’s nitric oxide nasal spray for COVID-19 in a number of Asian markets
Lannett to market Respirent’s generic of Spiriva Handihaler in the US
According to Lannett, the company has acquired US rights to market Respirents generic of Spiriva Handihaler tiotropium bromide DPI for a 10-year period, the company said. Lannett had already acquired US rights to Respirent's generic versions of Advair Diskus in 2019 and Flovent Diskus in 2020. Lannett CEO Tim Crew commented, "We continue to add drug and device … [Read more...] about Lannett to market Respirent’s generic of Spiriva Handihaler in the US
InnarisBio to develop sol-gel delivery technology for intranasal CNS drugs
Atai Life Sciences and University of Queensland technology transfer company UniQuest have announced the launch of a new company called InnarisBio, which will develop intranasal drug delivery technology for CNS drugs based on sol-gel technology developed by Queensland School of Pharmacy Senior Lecturer Harendra (Harry) Parekh. The sol-gel technology platform involves … [Read more...] about InnarisBio to develop sol-gel delivery technology for intranasal CNS drugs
Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain
Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda "a significant double-digit percent of the selling price" for Acorda to supply the product. The Inbrija DPI was approved in Europe for the … [Read more...] about Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain